You are here: Home » News-ANI » Health
Business Standard

Scientists find new way to suppress cancer immunity

ANI  |  WashingtonD.C [US] 

Contrary to earlier studies that identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, researchers from reveal a surprising role for these enzymes in subduing immunity.

Published in the journal Cell, the findings could have a clinical role in improving efficiency of immunotherapy drugs.

"Before our study, no one knew that the Hippo pathway was regulating immunogenicity," said first author Toshiro Moroishi.

Adding, "LATS1/2 deletion in cells improves tumor immunogenicity, leading to the destruction of cancerous cells by enhancing anti-tumor immune responses."

Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal but dysregulation contributes to development.

In vitro studies of Hippo pathway kinases LATS1/2 showed that the loss of these enzymes promoted cell proliferation and tumor survival.

In vivo research using immune-compromised mouse models also supports a tumor suppressor function of the Hippo pathway.

However, when Moroishi and team deleted LATS1/2 from mouse cells and examined tumor growth in models with healthy immune systems researchers found that immunogenicity -- the ability to stimulate an immune response -- improved, destroying cells.

Researchers caution that immune systems of mouse models are different from the human immune system so the response might be different and further studies are needed.

If the outcome proves to be the same, using a LATS1/2 inhibitor alone or in combination with an immune checkpoint inhibitor may stimulate the immune system of patients that previously did not respond to immunotherapy treatments.

Currently, most immunotherapy research focuses on targeting the immune system, but the new findings reveal that tumor cells may also be vulnerable to inhibitors.

"Inhibiting LATS1/2 could be an attractive approach to treat cancer," said Kun-Liang Guan.

Adding, "LATS is an ideal target because there are many kinase inhibitors that have been successfully developed as drugs.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Scientists find new way to suppress cancer immunity

Contrary to earlier studies that identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, researchers from University of California reveal a surprising role for these enzymes in subduing cancer immunity.Published in the journal Cell, the findings could have a clinical role in improving efficiency of immunotherapy drugs."Before our study, no one knew that the Hippo pathway was regulating immunogenicity," said first author Toshiro Moroishi.Adding, "LATS1/2 deletion in cancer cells improves tumor immunogenicity, leading to the destruction of cancerous cells by enhancing anti-tumor immune responses."Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal but dysregulation contributes to cancer development.In vitro studies of Hippo pathway kinases LATS1/2 showed that the loss of these enzymes promoted cell proliferation and tumor survival.In vivo research using immune-compromised mouse models also supports a tumor suppressor ...

Contrary to earlier studies that identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, researchers from reveal a surprising role for these enzymes in subduing immunity.

Published in the journal Cell, the findings could have a clinical role in improving efficiency of immunotherapy drugs.

"Before our study, no one knew that the Hippo pathway was regulating immunogenicity," said first author Toshiro Moroishi.

Adding, "LATS1/2 deletion in cells improves tumor immunogenicity, leading to the destruction of cancerous cells by enhancing anti-tumor immune responses."

Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal but dysregulation contributes to development.

In vitro studies of Hippo pathway kinases LATS1/2 showed that the loss of these enzymes promoted cell proliferation and tumor survival.

In vivo research using immune-compromised mouse models also supports a tumor suppressor function of the Hippo pathway.

However, when Moroishi and team deleted LATS1/2 from mouse cells and examined tumor growth in models with healthy immune systems researchers found that immunogenicity -- the ability to stimulate an immune response -- improved, destroying cells.

Researchers caution that immune systems of mouse models are different from the human immune system so the response might be different and further studies are needed.

If the outcome proves to be the same, using a LATS1/2 inhibitor alone or in combination with an immune checkpoint inhibitor may stimulate the immune system of patients that previously did not respond to immunotherapy treatments.

Currently, most immunotherapy research focuses on targeting the immune system, but the new findings reveal that tumor cells may also be vulnerable to inhibitors.

"Inhibiting LATS1/2 could be an attractive approach to treat cancer," said Kun-Liang Guan.

Adding, "LATS is an ideal target because there are many kinase inhibitors that have been successfully developed as drugs.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Scientists find new way to suppress cancer immunity

Contrary to earlier studies that identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, researchers from reveal a surprising role for these enzymes in subduing immunity.

Published in the journal Cell, the findings could have a clinical role in improving efficiency of immunotherapy drugs.

"Before our study, no one knew that the Hippo pathway was regulating immunogenicity," said first author Toshiro Moroishi.

Adding, "LATS1/2 deletion in cells improves tumor immunogenicity, leading to the destruction of cancerous cells by enhancing anti-tumor immune responses."

Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal but dysregulation contributes to development.

In vitro studies of Hippo pathway kinases LATS1/2 showed that the loss of these enzymes promoted cell proliferation and tumor survival.

In vivo research using immune-compromised mouse models also supports a tumor suppressor function of the Hippo pathway.

However, when Moroishi and team deleted LATS1/2 from mouse cells and examined tumor growth in models with healthy immune systems researchers found that immunogenicity -- the ability to stimulate an immune response -- improved, destroying cells.

Researchers caution that immune systems of mouse models are different from the human immune system so the response might be different and further studies are needed.

If the outcome proves to be the same, using a LATS1/2 inhibitor alone or in combination with an immune checkpoint inhibitor may stimulate the immune system of patients that previously did not respond to immunotherapy treatments.

Currently, most immunotherapy research focuses on targeting the immune system, but the new findings reveal that tumor cells may also be vulnerable to inhibitors.

"Inhibiting LATS1/2 could be an attractive approach to treat cancer," said Kun-Liang Guan.

Adding, "LATS is an ideal target because there are many kinase inhibitors that have been successfully developed as drugs.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard